Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience-Reference-Cited by-同舟云学术

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Published:2021-08-04 Issue:1 Volume:30 Page:585-591
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Loteta Barbara,Paviglianiti Annalisa,Naso Virginia,Ferreri Anna,Moscato Tiziana,Console Giuseppe,Canale Filippo Antonio,Irrera Giuseppe,Pugliese Marta,Di Costanzo Antonella,Provenzano Pasquale Fabio,Loddo Viviana,Porto Gaetana,Cusumano Giuseppa,Russo Letteria,Meliambro Nicola,Romeo Valentina,Porcino Domenico,Gallo Salvatore,Gangemi Tiziana,Rossetti Antonio Maria,Martino Massimo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-021-06472-7.pdf

Reference37 articles.

1. Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken) 1:e1127

2. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

3. Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M, Beggiato E, Butera S, Martella F, Dainese C, Cetani G, Scaldaferri M, Cattel F, Boccadoro M, Ferrero D, Bruno B, Cerrano M (2020) Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Ann Hematol 99:2197–2199

4. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO (2013) Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:344–356

5. Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation;Frontiers in Oncology;2023-11-21

2. Chinese expert consensus on prevention and treatment of delayed nausea and vomiting (2022 Edition);Oncology and Translational Medicine;2023-08